Sopharma AD
Sopharma AD is recorded as a service provider in 4 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 4 of 4 trials · Latest update first
An open-label, multi-center protocol for patients who have completed a previous Novartis sponsored Secukinumab study and are judged by the investigator to benefit from continued Secukinumab treatment
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A phase IIIb, multi-center, open-label, randomized study of tolerability and efficacy of oral asciminib versus nilotinib in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A Phase II, double-blind, randomized, multiple dose, cross over, three-treatment, three-period, six sequence placebo controlled trial to evaluate efficacy, pharmacokinetics (PK), pharmacodynamics (PD) and safety and tolerability of glycopyrronium (bromide) in children from 6 to less than 12 years of age with asthma
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg and 150 mg administered subcutaneously versus placebo, in combination with a glucocorticoid taper regimen, in patients with giant cell arteritis (GCA) (GCAptAIN)
Sponsor Novartis Pharma AG
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Sopharma AD?
The 2026-10-09 snapshot links Sopharma AD to 4 distinct CTIS trials. Recorded services include Re-labeling, Other: Re-labeling. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Sopharma AD?
The most frequently recorded therapeutic areas are Dermatology, Immunology, Musculoskeletal, Rheumatology. Recorded phases include Phase 4. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Sopharma AD conducted?
The linked trials record locations in 20 countries, including Bulgaria, Czechia, Germany, Spain, France. These are trial locations, not confirmed office locations or countries where Sopharma AD delivered services.
What can this page tell me about Sopharma AD's trial experience?
Browse 4 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Sopharma AD. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Sopharma AD